Petvivo Holdings Stock Price, News & Analysis

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has appointed Paula Wittler as the new Business Development Manager for the Western Region. Wittler brings over 25 years of experience in veterinary product management and marketing, previously working with Zoetis Animal Health. CEO John Lai emphasized her role in promoting Spryng™, a veterinary medical device designed to improve the treatment of lameness and joint issues in companion animals. PetVivo continues to focus on innovative biomedical devices and has a robust product pipeline, furthering its mission in animal health.

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will present at the H.C. Wainwright Global Investment Conference from September 12-14, 2022, in New York. CEO John Lai has recorded an overview of the company's business for this event. PetVivo is focused on developing and commercializing innovative medical devices for pets, with a portfolio of 17 products and 19 patents. Its lead product, SPRYNG™ with OsteoCushion™ technology, is available for managing joint-related afflictions in animals.

PetVivo Holdings, Inc. (Nasdaq: PETV) reported its first quarter fiscal 2023 financial results, showing a revenue increase to $58,174 from $4,145 in Q1 2022, driven by the commercialization of its Spryng™ device. Despite the revenue growth, the company faced a quarterly operating loss of $1,966,093 compared to $518,519 in the previous year, primarily due to increased costs associated with Spryng™ and other public company expenses. The net loss was $1,965,428, or ($0.20) per share. Cash and working capital stood at $4.4 million and $3.8 million, respectively.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) has announced the appointment of Rob Costantino and Leslie Coolidge to its Board of Directors. Mr. Costantino brings extensive financial and operational expertise from his prior roles as CEO and CFO at major corporations, including a pivotal turnaround at Mitsubishi Motors Credit. Ms. Coolidge, a former audit partner at KPMG, has significant experience in public company financial reporting. Both appointments are expected to enhance company strategy and governance, positioning PetVivo for growth in the innovative biomedical sector for companion animals.

PetVivo Holdings (NASDAQ: PETV, PETVW) announced the launch of PetVivo Cares, a nonprofit focused on improving the health of companion animals with joint issues. The initiative aims to donate 500 no-cost Spryng injections using OsteoCushion Technology to animal organizations in need. Led by Scott Herold, the program seeks to collaborate with private donors to enhance the quality of life for pets suffering from lameness and osteoarthritis. PetVivo's lead product, Spryng, is available for commercial sale in the U.S., supported by a pipeline of innovative veterinary medical devices.

PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) reported its financial results for the fiscal year ended March 31, 2022. Total revenues reached $115,586, a significant increase from $12,578 in the prior year, driven by the commercialization of its lead product, Spryng™. However, the company incurred an operating loss of $5,056,528 due to increased sales and marketing expenses totaling $4,970,960. The net loss for fiscal 2022 was $5,014,995, matching a loss of $0.57 per share, with cash reserves reported at $6.1 million.

PetVivo Holdings has entered a definitive distribution agreement with MWI Animal Health to promote its product, Spryng with OsteoCushion Technology, across the U.S. This partnership aims to enhance the company's presence in the animal health market, ensuring efficient distribution to veterinarians and pet owners. Spryng is designed to support joint health in companion animals, particularly addressing conditions like osteoarthritis. PetVivo is focused on innovative medical devices for animal health, holding multiple patents and a pipeline of products.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) plans to update investors on its MWI Distribution Services Agreement and share financial results for the fiscal year ending March 31, 2022. The update will occur on June 29, 2022, at 4:00 p.m. CT (5:00 p.m. ET). Attendees can access the live webcast through PetVivo's Investor Relations website, with a replay available afterward. The company, focused on innovative biomedical devices for companion animals, aims to enter the market swiftly with its products, including the lead therapy SPRYNG™ for osteoarthritis management in dogs and horses.

PetVivo Holdings (NASDAQ: PETV, PETVW) will report its financial results for the year ending March 31, 2022, on June 29, 2022, after market close. A conference call will take place at 4:00 p.m. CT to discuss these results. Investors can access the live webcast and related materials via the company's Investor Relations website. PetVivo is focused on developing medical devices and therapeutics for companion animals, emphasizing a strategy that leverages human therapies. The company has a pipeline of seventeen products and a portfolio of twenty-one patents.